Evidence map›Paper›PMID 37221489›Full record

ArticleBMC neurology2023

Elevated NT-proBNP predicts unfavorable outcomes in patients with acute ischemic stroke after thrombolytic therapy.

Zhuang Zhu, Bilal Muhammad, Bo Du, Ning Gu, Tian-Yue Meng, Shu Kan, Ying-Feng Mu, Yan-Bo Cheng, Shi-Guang Zhu, De-Qin Geng

Abstract read
In one paragraph

Article in BMC neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhuang Zhu *School of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221000, China.
Bilal Muhammad *Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Bo Du *Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Ning GuSchool of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221000, China.
Tian-Yue MengSchool of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221000, China.
Shu KanDepartment of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Ying-Feng MuDepartment of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Yan-Bo ChengDepartment of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Shi-Guang ZhuDepartment of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China. sgzhuxyfy@126.com.
De-Qin GengDepartment of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China. gengdeqin@126.com.

Funding

National Health Commission Brain Prevention Committee "Research and Promotion Project of Appropriate Technology Intervention for High-risk Groups of Stroke in China" (GN-2018R0009)Xuzhou Promoting Science and Technology Innovation Project (KC22241)
6 · The paper itself

Abstract

objectiveFew studies correlated n-terminal pro-brain natriuretic peptide (NT-proBNP) with early neurological deterioration (END) and prognosis of acute ischaemic stroke (AIS) patients with rt-PA intravenous thrombolysis. Therefore this study aimed to investigate the relationship between NT-proBNP and END, and prognosis after intravenous thrombolysis in patients with AIS.

methodsA total of 325 patients with AIS were enrolled. We performed the natural logarithm transformation on the NT-proBNP [ln(NT-proBNP)]. Univariate and multivariate logistic regression analyses were performed to assess the relationship between ln(NT-proBNP) and END, and prognosis and receiver operating characteristic (ROC) curves were used to show the sensitivity and specificity of NT-proBNP.

resultsAfter thrombolysis, among 325 patients with AIS, 43 patients (13.2%) developed END. In addition, three months follow-up showed a poor prognosis in 98 cases (30.2%) and a good prognosis in 227 cases (69.8%). Multivariate logistic regression analysis showed that ln(NT-proBNP) was an independent risk factor for END (OR = 1.450,95%CI:1.072 ~ 1.963, P = 0.016) and poor prognosis at three months follow-up (OR = 1.767, 95%CI: 1.347 ~ 2.317, P < 0.001) respectively. According to ROC curve analysis, ln(NT-proBNP) (AUC 0.735, 95%CI: 0.674 ~0.796, P < 0.001) had a good predictive value for poor prognosis, with a predictive value of 5.12 and sensitivity and specificity of 79.59% and 60.35% respectively. When combined with NIHSS to predict END(AUC 0.718, 95%CI: 0.631 ~ 0.805, P < 0.001) and poor prognosis(AUC 0.780, 95%CI: 0.724 ~ 0.836, P < 0.001), the predictive value of the model is further improved.

conclusionNT-proBNP is independently associated with END and poor prognosis in patients with AIS following intravenous thrombolysis and has a particular predictive value for END and poor prognosis.

Indexed as

Brain IschemiaIschemic StrokeStrokeHumansNatriuretic Peptide, BrainPeptide FragmentsThrombolytic TherapyNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Acute ischemic strokeEarly neurological deteriorationIntravenous thrombolysisNT-proBNPPrognosis

Identifiers

PMID37221489
PMCPMC10204306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.